Great Lakes Advisors LLC Takes $401,000 Position in TG Therapeutics, Inc. $TGTX

Key Points

• Great Lakes Advisors LLC has acquired a new stake in TG Therapeutics, purchasing 10,180 shares valued at approximately $401,000 in the first quarter.
• Goldman Sachs has upgraded TG Therapeutics to a "hold" rating with a price target of $37.00, and analysts have a consensus rating of "Moderate Buy" with a target of $46.25.
• Despite a significant year-over-year revenue increase of 92.1%, TG Therapeutics reported earnings per share of $0.17, missing analyst expectations of $0.32.

Great Lakes Advisors LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 10,180 shares of the biopharmaceutical company's stock, valued at approximately $401,000.

Several other institutional investors and hedge funds have also recently modified their holdings of TGTX. Vermillion Wealth Management Inc. bought a new position in shares of TG Therapeutics during the fourth quarter valued at $30,000. NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 823 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 433 shares in the last quarter. SVB Wealth LLC bought a new position in shares of TG Therapeutics during the first quarter valued at $37,000. Finally, USA Financial Formulas bought a new position in shares of TG Therapeutics during the first quarter valued at $57,000. 58.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $46.25.

TG Therapeutics Trading Down 0.9%

Shares of NASDAQ:TGTX opened at $32.16 on Friday. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of 86.92 and a beta of 1.88. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock's 50-day simple moving average is $32.38 and its two-hundred day simple moving average is $35.63. TG Therapeutics, Inc. has a 52-week low of $21.16 and a 52-week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company's revenue for the quarter was up 92.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. Analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the firm's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director directly owned 94,061 shares of the company's stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.64% of the company's stock.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.